Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Valeant Pharmaceuticals International Inc. Is Trading at 52-Week Highs: Should You Buy or Sell?

    | Karen Thomas, MSc, CFA

    Valeant Pharmaceutical International Inc. (TSX:VRX)(NYSE:VRX) is still in early stages of a comeback, with many hurdles to overcome.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.’s Recent Debt Offering a Genius Move

    | Chris MacDonald

    By refinancing $1.5 billion of debt due in 2020, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) CEO Joe Papa has continued to impress…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Surges ~12% in a Day: Why the Stock Could Easily Double in 2018

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) surged along with the biotech and pharma industry. Here's why investors should expect more big…

    Read more »

    Dividend Stocks

    New to Investing? Avoid These 5 “Rookie” Mistakes

    | Jason Phillips

    Follow these five tips that will help you avoid common pitfalls of investing in stocks such as Valeant Pharmaceuticals Intl…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: The Best Long-Term Rebound Play on the TSX?

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) looks like it's on the road to a rebound. Here's why investors may want to…

    Read more »

    Investing

    Aurora Cannabis Inc. Surges ~153% in a Month: Can it Catch Up to Canopy Growth Corp.?

    | Joey Frenette

    Are Aurora Cannabis Inc. (TSX:ACB) shares too hot to handle at current levels? Or is the company going after Canopy…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: If You’d Bought the Dip, You’re up

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has had a great month, and it could continue to ride that wave.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Opportunity or Value Trap?

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has shown signs of improvement under Joseph Papa. Should investors take a risk on the…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Is on the Path to Recovery

    | Stephanie Bedard-Chateauneuf, MBA

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) soared 17% on November 7 after the release of strong Q3 results and keeps rising.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Gives Back Controversial New Drug

    | Demetris Afxentiou

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) announced this week the sale of the controversial female-libido-enhancing drug Addyi.

    Read more »

    Investing

    Why Canada Goose Holdings Inc.’s Strong Q2 Shouldn’t Convince You to Buy the Stock

    | David Jagielski

    Canada Goose Holdings Inc. (TSX:GOOS)(NYSE:GOOS) had a very strong second quarter, but there are still some concerns investors should have about…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: A High-Risk/High-Reward Stock for Patient Rebound Hunters

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is picking up negative momentum. Should you buy the dip or follow the herd?

    Read more »